Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 18, Issue 4, 2015, Pages 333-337

  Moreira, D M ^a   Howard, L E ^b,c   Sourbeer, K N ^b,c   Amarasekara, H S ^b,c   Chow, L C ^b,c   Cockrell, D C ^b,c   Hanyok, B T ^b,c   Pratson, C L ^b,c   Aronson, W J ^d,e   Kane, C J ^f   Terris, M K ^g   Amling, C L ^h   Cooperberg, M R ^i,j,k   Liede, A ^l   Freedland, S J ^b,c  

^a MAYO CLINIC   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UCSD MEDICAL CENTER   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^l AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; GONADORELIN ANTAGONIST; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR GROWTH; WATCHFUL WAITING; BLOOD; BONE; BONE NEOPLASMS; CANCER GRADING; ODDS RATIO; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BONE AND BONES; BONE NEOPLASMS; HUMANS; MALE; NEOPLASM GRADING; ODDS RATIO; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SENSITIVITY AND SPECIFICITY;

EID: 84946717961     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2015.25     Document Type: Article

References (21)

1. Derleth CL, Yu EY. Targeted therapy in the treatment of castration-resistant prostate cancer. Oncology. 2013; 27: 620-628.
2. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology. 2013; 81: 1297-1302.
3. Nelius T, Reiher F, Lindenmeir T, Klatte T, Rau O, Burandt J, et al. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. Onkologie. 2005; 28: 573-578.
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-422.
5. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013; 14: 1193-1199.
6. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371: 424-433.
7. Slovin SF, Wilton AS, Heller G, Scher HI. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin CancerRes. 2005; 11: 8669-8673.
8. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, De KJ, et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol. 2004; 171: 2260-2264.
9. Dotan ZA, Bianco FJ Jr., Rabbani F, Eastham JA, Fearn P, Scher HI, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol. 2005; 23: 1962-1968.
10. Loeb S, Makarov DV, Schaeffer EM, Humphreys EB, Walsh PC. Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy. J Urol. 2010; 184: 157-161.
11. Moreira DM, Cooperberg MR, Howard LE, Aronson WJ, Kane CJ, Terris MK, et al. Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgendeprivation therapy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2014; 17: 91-96.
12. Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, et al. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2013; 16: 391-397.
13. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-1159.
14. Hamilton RJ, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr., Amling CL, et al. Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. J Urol. 2008; 179: 1785-1789; discussion 1789-1790.
15. Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4+3 and Gleason 3+4 tumors in a population based cohort. J Urol. 2009; 182: 2702-2707.
16. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294: 433-439.
17. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013; 190: 429-438.
18. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005; 23: 2918-2925.
19. Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011; 117: 2077-2085.
20. Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013; 31: 3800-3806.
21. Davis NB, Ryan CW, Stadler WM, Vogelzang NJ A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. BJU Int. 2005; 96: 787-790.